Fulltext

Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose

Christoph, Patricia ; Schuller, Christine ; Studer, Hanna ; Irion, Olivier ; De Tejada, Begoña Martinez ; Surbek, Daniel

In: Journal of Perinatal Medicine, 2012, vol. 40, no. 5, p. 469-474

Add to personal list
    Title
    • Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose
    Author
    • Christoph, Patricia. Department of Obstetrics and Gynecology, University Hospital Insel and University of Bern, Bern, Switzerland
    • Schuller, Christine. Department of Obstetrics and Gynecology, University Hospital Insel and University of Bern, Bern, Switzerland
    • Studer, Hanna. Department of Obstetrics and Gynecology, University Hospital Insel and University of Bern, Bern, Switzerland
    • Irion, Olivier. Department of Obstetrics and Gynecology, University Hospital, Geneva, Switzerland
    • De Tejada, Begoña Martinez. Department of Obstetrics and Gynecology, University Hospital, Geneva, Switzerland
    • Surbek, Daniel. Department of Obstetrics and Gynecology, University Hospital Insel and University of Bern, Bern, Switzerland
    Document Type
    • Postprint
    Language
    • English
    Published in
    • Journal of Perinatal Medicine, 2012, vol. 40, no. 5, p. 469-474. Walter de Gruyter
    Other Version
    OAI-PMH Identifier
    • oai:doc.rero.ch:295892
    Summary
    Objective: Oral iron substitution has shown to be insufficient for treatment of severe iron deficiency anemia in pregnancy. Ferric carboxymaltose is a new intravenous (i.v.) iron formulation promising to be more effective and as safe as iron sucrose. We aimed to assess side effects and tolerance of ferric carboxymaltose compared to i.v. iron sucrose in pregnant women. Methods: We performed a retrospective analysis of 206 pregnant women who were treated either with ferric carboxymaltose or iron sucrose for iron-deficiency anemia with intolerability to oral iron substitution, or insufficient hemoglobin increase after oral iron treatment, or need for rapid hemoglobin reconstitution. Primary endpoint was to evaluate the maternal safety and tolerability. Secondary endpoint was to assess efficacy of the treatment and exclude safety concerns for the fetus. Results: The incidence of drug-related adverse events was low and mostly mild in both groups. Mild adverse events occurred in 7.8% for ferric carboxymaltose and in 10.7% for iron sucrose. The mean rise of hemoglobin value was 15.4 g/L for ferric carboxymaltose and 11.7 g/L for iron sucrose. Conclusion: Ferric carboxymaltose administration in pregnant women is well tolerated and is not associated with any relevant clinical safety concerns. Ferric carboxymaltose has a comparable safety profile to iron sucrose but offers the advantage of a much higher iron dosage at a time reducing the need for repeated applications and increasing patients' comfort. Ferric carboxymaltose is the drug of choice, if i.v. iron treatment becomes necessary in the second or third trimester of pregnancy